Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (59)	8/31/2006 3:19:44 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 285

Whoa. Flat out "Not Approvable" for big pharma. Ouch. Were you following, was there an advisory committee meeting? An investor does have to worry a little about patient size in x1235 IV P3's. Act 1 and 3 were planned years ago in a different era. Acute setting, one to two treatments max, two trials I guess makes it work out. Plus, Act 4 safety trial to come.

To: dr.praveen who wrote (59)	8/31/2006 4:38:54 PM
From: kenhott	Read Replies (2) \| Respond to of 285

I think SNY has known about this for awhile. CRME should be about 6 months behind now on the oral. Edit: If the oral stays clean, CRME must partner this indication. The earlier the better and should focus on the big numbers and don't fight over $5-10m milestone. Get someone good and probably not Astella. Maybe they have gotten better.